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Treatment of Breast Cancer-Related Lymphedema
with Adipose-Derived Regenerative Cells and Fat
Grafts: A Feasibility and Safety Study
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ABSTRACT
Breast cancer-related lymphedema (BCRL) is a debilitating late complication with a lack of treat-
ment opportunities. Recent studies have suggested that mesenchymal stromal cells can alleviate
lymphedema. Herein, we report the results from the ﬁrst human pilot study with freshly isolated
adipose-derived regenerative cells (ADRC) for treating lymphedema with 6 months follow-up. Ten
BCRL patients were included. ADRC was injected directly into the axillary region, which was com-
bined with a scar-releasing fat graft procedure. Primary endpoints were change in arm volume.
Secondary endpoints were change in patient reported outcome and safety. The study is registered
with ClinicalTrials.gov (NCT02592213). During follow-up, a small volume reduction was noted but
was not signiﬁcant. Five patients reduced their use of conservative management. Patient-reported
outcomes improved signiﬁcantly over time. ADRCs were well tolerated and only minor transient
adverse events related to liposuction were noted. In this pilot study, a single injection of ADRC
improved lymphedema based on patient-reported outcome measures, and there were no serious
adverse events in the 6 months follow-up period. In addition, half of the patients reduced their
use of conservative management. ADRC therapy is a promising interventional therapy for alleviat-
ing lymphedema, but results need to be conﬁrmed in randomized clinical trials. STEM CELLS
TRANSLATIONAL MEDICINE 2017;6:1666–1672
SIGNIFICANCE STATEMENT
Lymphedema is one of the most serious and debilitating late complications following breast
cancer surgery with lackluster treatment opportunities. Cell therapy has shown promising
results in preclinical models of lymphedema. Autologous adipose tissue is the most convenient
source of cells for clinical therapy. In the present First in Human Pilot Study, it is shown that
treatment with autologous adipose-derived regenerative cells can alleviate symptoms and
reduce the need for other treatment options during the 6 months follow-up. The treatment
proved safe without any noteworthy adverse events. Randomized controlled trials will be
needed to verify the positive results.
INTRODUCTION
Lymphedema is one of the most common and
severe complications after breast cancer treat-
ment. Breast cancer-related lymphedema (BCRL)
occurs in 20%–30% of patients with lymph node
involvement [1] and manifests itself with excess
lymphatic ﬂuid and swelling of subcutaneous tis-
sues in the nearby arm due to obstruction and or
destruction of lymphatic vessels following surgical
treatment and/or radiation therapy. Lymphedema
impacts the patients’ lives both physically and psy-
chologically. Physically, the swelling can result in
fatigue, feeling of arm heaviness and tension,
reduced range of arm motion, as well as difﬁcul-
ties in performing daily activities, including
returning to work [2]. Psychologically, the swel-
ling can result in negative feelings with regard
to body image. In addition, lymphedema is
associated with increased risk of severe skin
infections [3].
Standard of care for lymphedema today is
conservative nonsurgical management, which
includes a mix of compression garments on the
affected arm(s), manual lymphatic drainage, exer-
cises, as well as meticulous skin care [4]. The non-
surgical management is only effective to a certain
extent with excess volume reductions in the range
of 20%–30% [5]. Each treatment is time consum-
ing, and treatment is lifelong because the underly-
ing problem has not been addressed [6]. Several
microsurgical approaches are being used
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experimentally with promising initial results; however, the evi-
dence for the efﬁcacy is poor [7, 8].
The potential ability to treat diseases through regeneration
has sparked the interest in cell therapy in almost all organ systems
[9], including BCRL [10, 11]. Two studies have so far examined the
efﬁcacy and safety of using bone marrow-derived mesenchymal
stromal cells to treat BCRL [10, 11]. These results were promising
with symptom relief and are supported by several preclinical stud-
ies using cell therapy to treat lymphedema [12]. In recent years,
several cell therapeutic protocols that utilize adipose-derived stro-
mal cells (also called stromal vascular fraction or adipose-derived
regenerative cells [ADRC]) have emerged. ADRCs are easily acces-
sible through liposuction and are an abundant cell source [13].
This pool of cells is, however, heterogeneous in nature and
includes stem cells, endothelial cells, pericytes, progenitor cells, as
well as hematopoietic cells. It has been proposed that these cells
may work in synergistic fashion, especially through paracrine
secretion of growth factors and cytokines [14, 15], and several
studies, including our unpublished data, indicate that ADRC likely
improves vascularity [16, 17].
We therefore recently performed a case study of ADRC trans-
plantation and fat grafting to alleviate lymphedema in one
patient. Interestingly, both a patient-reported and volumetric
improvement was noted [18]. To substantiate this promising
result, we herein tested efﬁcacy, safety, and feasibility of this pro-
cedure in the ﬁrst pilot study performed. We here report the
results from 10 patients with a 6-month follow-up period after
ADRC transplantation and fat grafting for BCRL.
MATERIALS AND METHODS
ADRC Transplantation and Fat Grafting
The procedures were performed under general anesthesia at the
Department of Plastic Surgery, Odense University Hospital.
Approximately 300 mL lipoaspirate from either thighs or abdomen
with water-jet-assisted liposuction (body-jet, Human med AG,
Schwerin, Germany, http://www.humanmed.com/en) was
obtained, and 30 mL was saved for lipotransfer to the axilla. After
decantation, the lipoaspirate for lipotransfer was injected in a fan-
shaped pattern for loosening the scar tissue. The patient was
transferred back to the ward awaiting cell injection to avoid occu-
pying the operating theatre for 2 hours as the ADRC were being
isolated. The remaining lipoaspirate was used for immediate
ADRC isolation using the Celution 800/IV system (Cytori Therapeu-
tics, San Diego, California, http://www.cytori.com/) according to
the manufacturer’s instructions. The ADRC was resuspended in
5 mL Lactated Ringer’s solution, and 1 mL was saved for in vitro
characterization. The remaining cells were injected in the axilla at
eight standardized points around the scar into the subcutaneous
plane.
Cell Characterization
Cells were counted with a NucleocounterNC-100 (ChemoMetec,
Denmark, https://chemometec.com/). ADRC surface marker anal-
ysis was performed as recommended internationally [15] and pre-
viously described [19]. The following antibodies were used
according to manufacturers (BD Biosciences, Albertslund, Den-
mark, http://www.bdbiosciences.com/us/home) recommenda-
tions: anti-CD235a (BV421, clone GA-R2/HIR2), anti-CD34
(PECF594, clone 581), anti-CD45 (FITC, clone HI30), CD31 (Alexa
Fluor 647, clone WM59), CD73 (APC, clone AD2), CD90 (APC,
clone 5E10), and appropriate isotype (for single stains) or FMO
control (for CD34 on multistain). Sample acquisition was per-
formed on a BD LSRII ﬂow cytometer and analyzed using the FACS-
Diva software v8.0.1 (BD Biosciences, Albertslund, Denmark,
http://www.bdbiosciences.com/us/home) and FlowJo 10.0.8r1
(Flowjo, LLC, Ashland, Oregon, US https://www.ﬂowjo.com/). Cell
doublets were excluded from all analyses by sequential gating
through forward and side scatter height/width plots.
The percentage of ﬁbroblastoid colony-forming units (CFU-F)
in each ADRC sample was determined by seeding cells at low den-
sity (4 densities in triplicate ranging from 28–280 live nucleated
cells per cm2) in dulbecco’s modiﬁed eagle medium (DMEM) with
1 g/L glucose, 10% fetal bovine serum (FBS), 1%PS, culturing for
14 days, and counting hematoxylin and eosin (HE)-stained colo-
nies comprising >50 cells. The differentiation potential of the
adipose-derived stem cells within the ADRC was tested using adi-
pogenesis, osteogenesis, and chondrogenesis differentiation kits
from StemPro (Thermo Fisher Scientiﬁc, Denmark, https://www.
thermoﬁsher.com/us/en/home.html) as recommended by the
manufacturer.
Volumetric Outcome Assessment
Arm volume was calculated as previously described [20]. Brieﬂy,
circumference measurements were made at ﬁve points on each
arm: wrist, largest point on lower arm, elbow, middle of upper
arm, and proximal on the upper arm. The length between each
point was measured, and at each time point the same sites were
measured. Based on these ﬁve measurements, the arm was
divided in four segments and the volume of each segment was
calculated based on the truncated cone formula.
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Where V is the segment volume, h is the length of the segment,
and C1 and C2 are the two circumference measurements at the
two ends of the segment. Arm volume was calculated as the sum
of the four segment volumes. Excess arm volume was calculated
as the volume difference between the two arms.
Arm volume was also evaluated by DXA, which was performed
preoperatively and 3 months and 6 months postoperatively. The
DXA was performed as two whole body scans with the patient
lying in a modiﬁed position enabling the arm to be free from the
trunk. For analysis, a blinded assessor drew the region around the
arm with the proximal end of the arm deﬁned as just below the
deltoid muscle, which is easily visualized on the DXA. The bone
mineral content, fat mass, and lean mass were used to calculate a
total arm volume based on known densities as has been previ-
ously described [21].
Patient-Reported Outcome Assessment
Patients were asked to rate the feeling of heaviness in the lymphe-
dema arm on a numerical rating scale ranging from 0 to 10, with 0
meaning no heaviness at all and 10 signifying the worst heaviness
imaginable. Similarly, the patients were asked to rate the feeling
of tension in the lymphedema arm. In addition, two question-
naires were used: the disabilities of the arm, shoulder and hand
(DASH) outcome questionnaire [25] as well as the Lymphedema
Quality-of-Life (LYMQOL) questionnaire [26] were ﬁlled out preop-
eratively and at each time point after treatment.
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Safety Assessment
Safety was evaluated by a speciﬁc questionnaire given to the
patients postoperatively, which was to be ﬁlled out prospectively
during the ﬁrst month following treatment. The questionnaire
included questions regarding redness, swelling, itching, pain
(which was not handled sufﬁciently with over the counter medi-
cine), infection, other discomfort, and having seen their family
doctor for any reason. Additionally, at the postoperative visits,
adverse events were recorded by inspection of the injection and
donor site and posing an open question, “Did you experience any
other discomfort related to the operation since the last visit?”
Statistical Analysis
Statistical analysis was performed with GraphPad Prism 6.0 for
Windows (GraphPad Software, La Jolla, California, www.graphpad.
com). Subjective scores on visual analogue scale and question-
naire outcomes were analyzed by Friedman’s test for multiple
non-parametric comparisons with Dunn’s post-hoc test for multi-
ple comparisons. Volumetric changes were analyzed using One-
way analysis of variance (ANOVA) with Dunnett post-hoc test for
multiple comparisons. For subgroup analysis based on Interna-
tional Society of Lymphology (ISL) stage, a two-way ANOVA was
performed with Tukey’s test for multiple comparisons. A two-
tailed p value of less than .05 was considered signiﬁcant.
RESULTS
Study Design and Patient Characteristics
This study was conducted as an open–label, single-arm, single-
center feasibility and safety study in patients with breast cancer-
related lymphedema of the upper extremity (ClinicalTrials.gov
NCT02592213). The study was approved by The Regional Commit-
tees on Health Research Ethics for Southern Denmark (3-3013-
1572/1), who had oversight of the study. The study was registered
with The Danish Data Protection Agency (2008-58-0035).
The aim was to include 10 patients for treatment, and 34
patients were screened for eligibility, of whom 11 were found to
be eligible. The reason for the extra included patient was due to
non-protocolled treatment of the very ﬁrst patient, who was
therefore excluded from analysis (supplemental online Fig. 1).
Inclusion period ranged from December 2015 to May 2016, and
all patients were treated between January and May 2016.
Eligible patients had to fulﬁll the following criteria: diagnosed
with upper extremity lymphedema due to previous breast cancer
treatment with lymph node involvement, recurrence-free for min-
imum 1 year, unilateral disease, lymphedema ISL stage I or II, cir-
cumference of arm a minimum of 2 cm larger than the healthy
side, age between 18 and 70 years old, The American Society of
Anesthesiologists Physical Status classiﬁcation system (ASA) score
1 or 2, able to give written informed consent, and able to under-
stand the Danish language. Additionally, they were excluded if
they had a history of other cancer types, had diabetes mellitus,
had psychiatric conditions that could interfere with participation,
or used tobacco, which was not ceased in relation to the proce-
dure (supplemental online Fig. 1). The ages of the 10 included
patients ranged from 34–68 years (54.5 [12.3], median [interquar-
tile range {IQR}]). Only two participants had ISL stage U lymphe-
dema and the remaining participants had stage II (Fig. 1A and 1B).
The majority of patients had received both radiation and chemo-
therapy for the primary breast cancer treatment, and the duration
of lymphedema prior to inclusion in the trial was 28.5 (17.3;
median [IQR]) months (Fig. 1B).
ADRC Isolation and Transplantation
For the ADRC treatment, all patients underwent liposuction under
general anesthesia, during which approximately 300 mL of lipoas-
pirate (Fig. 2A) was harvested from either the abdomen or thighs
depending on availability and preference of the patient. The ARDC
isolation using the automated Celution system and cellular/bio-
chemical characterization (Fig. 2B) has previously been described
[19]. In addition, a lipoaspirate was harvested for immediate graft-
ing in the axilla, where fat was injected in a standard fan shaped
pattern to release scar tissue (28.1, 7.8 mL [mean, SD]; Fig.2C).
ADRCs (5.37 3 107, 1.08 3 107 cells [mean, SD]) were injected in
the axilla 2 hours later (Fig. 2D).
The characteristics of the isolated ADRC were comparable to
those previously reported by us [19], including yield (ADRC cells/g
fat tissue, 2.1 3 105, 4.2 3 104 [mean, SD]), cell size (10.8, 0.2
[mean, SD]), viability (83.4, 3.0 [mean, SD]), and percentage of
Figure 1. Patient overview. (A): Representative photo of breast cancer-related lymphedema in the left arm compared with the healthy con-
tralateral side. (B): Table showing baseline characteristics of included patients. Patient ID 02 was excluded due to non-protocolled treatment
as described in the manuscript. Abbreviations:1, yes; -, no; BMI, body mass index; CT, chemotherapy; ISL stage, International Society of Lym-
phology stage; Pt. ID, patient identiﬁcation; RT, radiation therapy.
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ﬁbroblastoid colony forming units (%CFU-F, 0.4, 0.4 [mean, SD]). A
large proportion of the ADRC expressed the surface markers CD34
(43.1, 14.5% [mean, SD]; Fig. 2E) and CD90 (70.2, 9.3% [mean,
SD]; Fig. 2F), whereas CD31 and CD73 each deﬁned smaller subpo-
pulations (19.4%, 8.1% and 20.5%, 17.7%, respectively [mean,
SD]; Fig. 2G and 2H). The amount of blood as determined by the
hematopoietic and erythropoietic markers CD45 (17.1, 5.7%
[mean, SD]; Fig. 2I) and CD235a (33.1, 16.0% [mean, SD]; Fig. 2J),
respectively, was similar between samples. The fraction of stromal
stem cells as deﬁned phenotypically by the markers CD235a-
CD45-CD31-CD341 encompassed 24.96 8.4% (mean6 SD; Fig.
2K) of the parent ADRC, whereas the fraction of endothelial pro-
genitor cells CD235a-CD45-CD311CD341 comprised
14.16 6.1% (mean6 SD; Fig. 2L).
Safety and Lymphedema Alleviation Using ADRC
Transplantation and Fat Grafting
In total, nine minor adverse events in 4/10 patients were noted in
the follow-up period. Three patients noted bruising of the donor
site following liposuction, accompanied by pain in two cases.
Another patient noted itching of the axilla and donor site. All pain
and itching resolved spontaneously within the ﬁrst week after
treatment. One patient complained of back pain 2 weeks after
treatment, for which she sought a chiropractor. At 3 months
follow-up, one patient complained of reduced sensation at the
donor site, which resolved spontaneously at 6 months follow-up.
One patient noted a slight irregularity in the skin surface at the
donor site. All the above events are expected complications of lip-
osuction and fat grafting and were therefore not attributed to the
ADRC transplantation. There was no evidence of cancer recur-
rence during the follow-up period.
Patients were evaluated 1, 3, and 6 months following ADRC
transplantation. In general, the patients reported a decrease of
their lymphedema symptoms over time (Fig. 3; see Materials and
Methods for detailed assessment tools). The median (IQR, n5 10)
score for heaviness of the arm at baseline was 5.5 (4.0), after 1
month 4.0 (2.5; p5 .2498), after 3 months 3.5 (3.5; p5 .0097),
and after 6 months 2.5 (4.3; p5 .0030; Fig. 3A). Likewise, we
found a median score for arm tension at baseline to be 5.0(1.5),
after 1 month 3.0 (3.0; p5 .0281), after 3 months 3.0 (2.3;
p5 .0459), and after 6 months 2.5 (4.3; p5 .0097; Fig. 3B). Finally
the DASH questionnaire was also used, in which the median score
Figure 2. The procedure and cell characterization. (A): Approximately 300 mL of lipoaspirate was harvested for adipose-derived regenerative
cell (ADRC) isolation. (B): ADRC were isolated using the automated Celution IV system yielding a 5-mL cell suspension in about 2 hours. (C):
During surgery, 20–30 mL of lipoaspirate was injected in the axilla in a fan-shaped pattern to loosen scar tissue. (D): Immediately following
ADRC isolation, the cell suspension was injected subcutaneously in the axilla. Flow cytometric evaluation of ADRC surface markers was per-
formed on fresh cells and analyzed for CD34 (E), CD90 (F), CD31 (G), CD73 (H), CD45 (I), CD235a (J). The stromal stem cell subpopulation was
deﬁned as CD235a-CD45-CD31-CD341 (K) and the endothelial progenitor cell subpopulation was deﬁned as CD235a-CD45-CD311CD341 (L).
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at baseline was 21.3 (23.5), after 1 month 10.0 (14.5; p5 .0097),
after 3 months 10.4 (24.8; p5 .0281), and after 6 months
12.9 (26.0; p5 .0168; Fig. 3C). Moreover, ﬁve patients reduced their
use of conservative treatment. A signiﬁcant mood improvement
was also observed at 3 and 6 months follow-up with the LYMQOL
questionnaire. However, only minor insigniﬁcant improvements
were reported in the other LYMQOL subscales (supplemental online
Table 1).
The change in excess arm volume was evaluated with two
separate methods. As previously described [20], the volume of
the arm can be estimated by ﬁve manual circumference measure-
ments along the arm using the truncated cone formula (Fig. 4A).
Figure 3. Patient reported outcome evaluation. Patient-reported outcome was evaluated after 1, 3, and 6 months following treatment.
There was a signiﬁcant improvement in patient reported outcomes based on the degree of heaviness (A): as well as tension (B): in the arm
measured on numerical rating scales (0–10) as well as the DASH questionnaire (C). Abbreviations: DASH, disabilities of the arm, shoulder and
hand; IQR, interquartile range.
Figure 4. Volumentric outcome evaluation. (A): Volume was calculated manually by circumference measurements at ﬁve points along the
arm and measurement of the distance between each point. A transient signiﬁcant reduction in arm volume was seen after 1 month but
results were insigniﬁcant after 3 and 6 months. (B): Volume was also assessed by DXA after 3 and 6 months after treatment. A subregion was
drawn around the arm and based on known densities of bone, fat, and lean tissue types, the volume was calculated. Similar to the circumfer-
ence measurements, volume change over time assessed by DXA also showed a small non-signiﬁcant decrease at the 3 and 6 month time
points. Abbreviation: DXA, dual-energy x-ray absorptiometry.
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The arm volume can also be described by dual-energy x-ray
absorptiometry (DXA; Fig. 4B). A subregional analysis of the arm
will reveal the mass of bone, fat and lean mass, and, based on
known densities of the tissue types, the volume of the arm can be
calculated [21]. For each method the difference in arm volume
between the lymphedematous and healthy arm was deﬁned as
excess arm volume. Although a slight difference in absolute vol-
ume is present (Fig. 4A and 4B) between the results obtained
from the two methods, they correlated signiﬁcantly (r5 0.848,
p< .0001, Pearson). A modest decrease in excess arm volume
was observed after 1 month; however, after 3 and 6 months, the
change was still decreased but failed to meet the signiﬁcance level
(Fig. 4A and 4B).
We performed subgroup analysis based on ISL stage I (n5 2)
and II (n5 8). Visual interpretation showed a trend towards
greater response for ISL stage I patients (supplemental online Fig
2). Two-way ANOVA testing revealed no signiﬁcant differences
between the groups but for feeling of tension (p5 .0583), DASH
questionnaire (p5 .0971), as well as volume (p5 .0947). The p
value neared signiﬁcance despite the low number of patients.
Interestingly for volume, there was a signiﬁcant decrease in vol-
ume after 6 months for ISL stage I (p5 .0253) but not ISL stage II
patients.
DISCUSSION
In this clinical trial, we show that a single treatment of cell-
assisted lipotransfer using ADRCs can alleviate lymphedema symp-
toms and moreover reduce the need for conservative treatment
in 50% of patients. The data from the numerical rating scales and
the DASH questionnaire were signiﬁcant, whereas only minimal
trends were seen for the LYMQOL questionnaire, which concerns
quality-of-life perception. Four patients had previous cellulitis/ery-
sipelas infection in their lymphedema arm, and there were no epi-
sodes of infection in the arm following treatment, a ﬁnding which
has also been documented for microsurgical procedures [22].
Although, our qualitative measures all point towards the con-
clusion that ADRC-assisted lipotransfer is a promising future inter-
vention for lymphedema patients, we did not ﬁnd any signiﬁcant
reduction in excess volume as measured by two quantitative tech-
niques. The latter may be explained by the use of adjunct conserv-
ative management in our patients, because Hou et al. recently
reported that patients without prior conservative treatment expe-
rience a substantial volume reduction 3 and 12 months after bone
marrow-derived stromal cell treatment as compared to combined
treatment that includes conservative management [10]. Likewise,
Maldonado et al. have shown that bone marrow-derived stromal
cell therapy alone was as effective as compression therapy with a
200-mL volume reduction in the lymphedema arm [11]. In this
regard, it seems limiting for our assessment of volumes (manual
and DXA) that our patients wore their compression garment up
until the point of examination, leaving no window for “stress
testing” of the lymphatic drainage of the arm. Currently, we are
developing a new quantitative measure based on lymphoscintigra-
phy that enables us to determine changes in lymphatic drainage
when using conservative treatment in parallel.
Importantly, we did not observe any adverse events within a
6-month time frame. While this is an important result, a long-
term evaluation of the safety is necessary, especially regarding the
risk of cancer recurrence, in light of ADRC injection into an area
with previous malignancy [23]. Yet hereto, the safety proﬁles of
using ADRC transplantation and fat grafting are in agreement with
other recent studies using bone marrow-derived mesenchymal
stromal cells for lymphedema [10, 11]. Still, the ﬁeld needs to
document long-term (years) safety of cellular therapy in these
patients.
The study was not without limitations. First, the trial was
unblinded. It is possible that the added visits and the patients’
own expectations of stem cell therapy may have caused a placebo
effect. The trial was also one-armed, and the lack of a control
group is a weakness. However, lymphedema is a condition that
very rarely improves and, if anything, only worsens, so it could be
speculated that any positive change might be attributed to the
given treatment. Another potential weakness lies in the patient
population, as most patients were late ISL stage II, in which
chronic changes are dominant. ISL stage I patients might have a
higher chance of successful treatment based on our very prelimi-
nary subgroup analysis, which is in agreement with microsurgical
procedures, where it is generally accepted that the chance for suc-
cessful treatment is greatest for early-stage lymphedema without
chronic changes [24]. It is important to increase the chance of
treatment success through the optimization of the selection crite-
ria for patients. We aimed to harvest of 300 mL lipoaspirate for
cell isolation, as we estimated that it could be harvested from
almost any patient, so that the treatment was made as uniform as
possible. Further studies are needed to determine an optimal
dose. Additionally, it will be interesting to examine in the future if
either ADRC or fat grafting can stand alone as treatment, which
could possibly simplify the procedure.
CONCLUSION
The principal ﬁndings in this study are that autologous ADRC com-
bined with a scar-releasing fat graft was safe during the 6 months
follow-up period and can alleviate symptoms of breast cancer-
related lymphedema, minimizing the need for conservative treat-
ment. As the effect was primarily noted on patient-reported out-
comes, it is important to conﬁrm the beneﬁt of this treatment
modality in a properly blinded randomized controlled trial, in
which sensitive methods to quantify excess volumes are included
also included and patients are followed for several years to ensure
long-term safety. Finally, future studies may also seek to test if the
observed beneﬁcial effect is caused by the ADRC or the fat graft
alone, or a combination.
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the subgroup analysis of the patient-reported outcomes of feeling
of heaviness and tension in the arm grouped by ISL stage.
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